Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial
{{output}}
Aims: Despite the increasing use of stereotactic ablative radiotherapy (SABR) for oligometastatic cancer, at present, accurate models to predict the time until disease progression are lacking. The study developed radiomics models... ...
